Recently, classifying endometrial cancer by the presence of specific markers—such as polymerase-epsilon (POLE) exonuclease domain mutations (EDMs), protein 53 (p53) immunohistochemistry, and mismatch repair (MMR) proteins has become a crucial tool in its treatment (20). The gene discussed is TP53; the disease is endometrial cancer.